Changes in ctDNA can predict long-term outcomes in certain patients with metastatic CRC on immune checkpoint inhibitors.

Using ctDNA test results to guide adjuvant treatment with pembrolizumab can provide benefits in patients with dMMR solid tumors, data suggest.

Treatment options for DMMR colorectal cancer can be tricky. On one hand, it tends to be more resistant to chemotherapy, but researchers have now been making inroads with immunotherapy.

Patients with multiple types of locally advanced, mismatch repair–deficient (dMMR) tumors were able to avoid surgery following treatment with the PD-1 inhibitor dostarlimab (Jemperli, GSK ...

The FDA has approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for unresectable or metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer.

MOMA Therapeutics, a clinical-stage biopharmaceutical company discovering and developing a new generation of precision therapeutics, today announced that the first patient has been dosed in its Phase ...

The FDA has approved Jemperli plus chemotherapy for dMMR/MSI-H primary advanced or recurrent endometrial cancer.

PHILADELPHIA, June 03, 2024--Jemperli trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced dMMR rectal cancer ...

The combination of Opdivo and Yervoy is supported by updated results as a standard of care for MSI-H or dMMR metastatic colorectal cancer.

Another study shows good results with neoadjuvant immunotherapy in patients with locally advanced dMMR/MSI-H colorectal cancer, leading the authors to suggest it as a new standard of care.

Keytruda was also studied in people with advanced microsatellite instability-high or mismatch repair-deficient (MSI-H/dMMR) endometrial cancer who had received previous treatment for their cancer.

Neoadjuvant Keytruda for patients with deficient DNA mismatch repair colon cancer resulted in a pathological complete response rate of 44%.